Significance of lipid-associated XXXX and CA 19-9 as @entity5 markers for @entity1358 .

@entity1 @entity3167 @entity5 @entity1735 @entity1358 @entity35419 @entity694
Numerous @entity5 , including colonic, lung, stomach, and prostate, have been found to have increased concentrations of lipid-associated @entity3167 ( @entity35419 ). CA 19-9 is a @entity1735 antigen found on the membrane surface of pancreatic, gastric, and @entity694 . A prospective study involving 25 @entity1 (15 males, 10 females) with @entity1358 ( @entity1358 ) was undertaken to examine the clinical value of these two markers. @entity1 ' ages ranged from twenty-five to seventy-seven years (mean 56 years). The group consisted of 9 Stage I, 1 Stage II, 5 Stage III, and 10 Stage IV @entity1 . Twenty three of the 25 had known disease present when tested. Eleven @entity1 with no known @entity5 were used as an age-matched control group. Sixteen of the 23 @entity1 with known disease (70%) had elevated LASA values. Nine of the 11 control @entity1 (82%) had normal LASA values. Three of 7 @entity1 with values obtained pre- and post-nephrectomy showed levels returned to normal after nephrectomy; 3 had persistent LASA elevation and were found to have either metastatic or recurrent disease, and 1 had a persistent elevation of his LASA value without known metastatic or recurrent disease. When the 23 @entity1 with known disease were compared according to stage, 62 percent of Stages I and II, 80 percent of Stage III, and 70 percent of Stage IV had elevated LASA values. There was no statistically significant difference between LASA values and @entity5 stage. CA 19-9 values obtained in 15 of 25 @entity1 with @entity1358 were within normal range.
